44 states accuse big pharma of price fixing generics market
13-05-2019
Teva settles Sensipar patent dispute with Amgen
04-01-2019
FTC agrees to re-open Actavis and Watson merger decision
19-12-2018
parbradyphoto / iStockphoto.com
Teva Pharmaceutical and the US Federal Trade Commission (FTC) have reached a settlement to end their long-running battles over so called “pay-for-delay” agreements in the pharmaceutical industry.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Teva Pharmaceutical, Federal Trade Commission, generic drugs, reverse-payment, antitrust
